Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nathalie Castéran"'
Autor:
Martine Humbert, Nathalie Castéran, Sébastien Letard, Katia Hanssens, Juan Iovanna, Pascal Finetti, François Bertucci, Thomas Bader, Colin D Mansfield, Alain Moussy, Olivier Hermine, Patrice Dubreuil
Publikováno v:
PLoS ONE, Vol 5, Iss 3, p e9430 (2010)
BackgroundTyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFRalpha/beta, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been repor
Externí odkaz:
https://doaj.org/article/c0ecd19186db4507849797a53ce894ca
Autor:
Patrice Dubreuil, Sébastien Letard, Marco Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S Leventhal, Colin D Mansfield, Alain Moussy, Olivier Hermine
Publikováno v:
PLoS ONE, Vol 4, Iss 9, p e7258 (2009)
BackgroundThe stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine k
Externí odkaz:
https://doaj.org/article/63537d296c7e47bf89a26c076d6d1533
Autor:
Cécile Cocude, Edith Darcissac, Joëlle Dewulf, George M. Bahr, Marie-José Truong, Nathalie Castéran, Corinne Amiel, Yves Mouton, André Capron
Publikováno v:
Journal of Virology. 75:6941-6952
Recent developments in antiretroviral therapy have led to substantial advances in the management of human immunodeficiency virus type 1 (HIV-1)-infected patients. However, it is becoming evident that potent antiretrovirals do not seem to be sufficien
Autor:
Carrie J. Riendeau, Edith Darcissac, Nathalie Castéran, André Capron, Hardy Kornfeld, George M. Bahr, Vincent Vidal
Publikováno v:
European Journal of Immunology. 31:1962-1971
The smallest unit of bacterial peptidoglycans known to be endowed with biological activities is muramyl dipeptide (MDP). A clinically acceptable synthetic derivative of MDP, namely murabutide (MB), has been found to present interesting pharmacologica
Autor:
Kahina Hammam, Magali Saez-Ayala, Etienne Rebuffet, Laurent Gros, Sophie Lopez, Berengere Hajem, Martine Humbert, Emilie Baudelet, Stephane Audebert, Stephane Betzi, Adrien Lugari, Sebastien Combes, Sebastien Letard, Nathalie Casteran, Colin Mansfield, Alain Moussy, Paulo De Sepulveda, Xavier Morelli, Patrice Dubreuil
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Masitinib is a protein kinase inhibitor that sensitises refractory pancreatic adenocarcinoma cells to treatment with the nucleoside analog gemcitabine. Here the authors show that Masitinib activates deoxycytidine kinase to enhance phosphorylation of
Externí odkaz:
https://doaj.org/article/17f65d9ef23b487fb909bb37564ae125